Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

NQO1gene rs1800566 variant is not associated with risk for multiple sclerosis

Authors: José A G Agúndez, Elena García-Martín, Carmen Martínez, Julián Benito-León, Jorge Millán-Pascual, Patricia Calleja, María Díaz-Sánchez, Diana Pisa, Laura Turpín-Fenoll, Hortensia Alonso-Navarro, Lucía Ayuso-Peralta, Dolores Torrecillas, José Francisco Plaza-Nieto, Félix Javier Jiménez-Jiménez

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

A possible role of oxidative stress in the pathogenesis of multiple sclerosis (MS) and in experimental autoimmune encephalomyelitis has been suggested. The detoxification enzyme NAD(P)H dehydrogenase, quinone 1 (NQO1) has been found up-regulated in MS lesions. A previous report described an association between the SNP rs1800566 in the NQO1 gene and the risk for MS in the Greek population. The aim of this study was to replicate a possible influence of the. SNP rs1800566 in the NQO1 gene in the risk for MS in the Spanish Caucasian population.

Methods

We analyzed allelic and genotypic frequency of NQO1 rs1800566 in 290 patients with MS and 310 healthy controls, using TaqMan Assays.

Results

NQO1 rs1800566 allelic and genotypic frequencies did not differ significantly between MS patients and controls, and were unrelated with age of onset of MS, gender, and clinical type of MS.

Conclusions

Our results indicate that NQO1 rs1800566 does not have an effect on MS disease risk.
Appendix
Available only for authorised users
Literature
1.
Giordano M, D'Alfonso S, Momigliano-Richiardi P: Genetics of multiple sclerosis: linkage and association studies. Am J Pharmacogenomics. 2002, 2: 37-58. 10.2165/00129785-200202010-00004.CrossRefPubMed
2.
Dyment DA, Ebers GC, Sadovnick AD: Genetics of multiple sclerosis. Lancet Neurol. 2004, 3: 104-110. 10.1016/S1474-4422(03)00663-X.CrossRefPubMed
3.
Ramagopalan SV, Deluca GC, Degenhardt A, Ebers GC: The genetics of clinical outcome in multiple sclerosis. J of Neuroimmunol. 2008, 201–202: 183-199.CrossRef
4.
Pugliatti M, Harbo HF, Holmøy T, Kampman MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand. 2008, Suppl 188: 34-40.CrossRef
5.
Duque B, Sepulcre J, Bejarano B, Samaranch L, Pastor P, Villoslada P: Memory decline evolves independently of disease activity in MS. Mult Scler. 2008, 4: 947-953.CrossRef
6.
Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, et al: Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011, 476: 214-219. 10.1038/nature10251.CrossRefPubMedPubMedCentral
7.
Patsopoulos NA, Bayer Pharma MS Genetics Working Group, Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist, ANZgene Consortium, GeneMSA, International Multiple Sclerosis Genetics Consortium: Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011, 70: 897-912. 10.1002/ana.22609.CrossRefPubMedPubMedCentral
8.
Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF, Agliardi C, Alfredsson L, Alizadeh M, International Multiple Sclerosis Genetics Consortium (IMSGC), et al: Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013, 45: 1353-1360. 10.1038/ng.2770.CrossRefPubMedPubMedCentral
9.
Gourraud PA, Harbo HF, Hauser SL, Baranzini SE: The genetics of multiple sclerosis: an up-to-date review. Immunol Rev. 2012, 248: 87-103. 10.1111/j.1600-065X.2012.01134.x.CrossRefPubMed
10.
LeVine SM: The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses. 1992, 39: 271-274. 10.1016/0306-9877(92)90121-R.CrossRefPubMed
11.
Newcombe J, Li H, Cuzner ML: Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol & Appl Neurobiol. 1994, 20: 152-162. 10.1111/j.1365-2990.1994.tb01174.x.CrossRef
12.
Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H: Oxidative damage in multiple sclerosis lesions. Brain. 2011, 134: 1914-1924. 10.1093/brain/awr128.CrossRefPubMedPubMedCentral
13.
van Horssen J, Schreibelt G, Bö L, Montagne L, Drukarch B, van Muiswinkel FL, de Vries HE: NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radic Biol Med. 2006, 41: 311-317. 10.1016/j.freeradbiomed.2006.04.013.CrossRefPubMed
14.
van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, de Vries HE: Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med. 2008, 45: 1729-1737. 10.1016/j.freeradbiomed.2008.09.023.CrossRefPubMed
15.
Bizzozero OA, DeJesus G, Callahan K, Pastuszyn A: Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J Neurosci Res. 2005, 81: 687-695. 10.1002/jnr.20587.CrossRefPubMed
16.
Zheng J, Bizzozero OA: Decreased activity of the 20S proteasome in the brain white matter and gray matter of patients with multiple sclerosis. J Neurochem. 2011, 117: 143-153. 10.1111/j.1471-4159.2011.07182.x.CrossRefPubMedPubMedCentral
17.
Langemann H, Kabiersch A, Newcombe J: Measurement of low molecular-weight antioxidants uric acid tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol. 1992, 32: 248-252. 10.1159/000116835.CrossRefPubMed
18.
van Horssen J, Drexhage JA, Flor T, Gerritsen W, van der Valk P, de Vries HE: Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med. 2010, 49: 1283-1289. 10.1016/j.freeradbiomed.2010.07.013.CrossRefPubMed
19.
Wilhelmus MM, van der Pol SM, Jansen Q, Witte ME, van der Valk P, Rozemuller AJ, Drukarch B, de Vries HE, Van Horssen J: Association of Parkinson disease-related protein PINK1 with Alzheimer disease and multiple sclerosis brain lesions. Free Radic Biol Med. 2011, 50: 469-476. 10.1016/j.freeradbiomed.2010.11.033.CrossRefPubMed
20.
McMahon JM, McQuaid S, Reynolds R, FitzGerald UF: Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis. Mult Scler. 2012, 18: 1437-1447. 10.1177/1352458512438455.CrossRefPubMed
21.
Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, Mahad D, Bradl M, van Horssen J, Lassmann H: NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain. 2012, 135: 886-899. 10.1093/brain/aws012.CrossRefPubMedPubMedCentral
22.
Choi IY, Lee SP, Denney DR, Lynch SG: Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T. Mult Scler. 2011, 17: 289-296. 10.1177/1352458510384010.CrossRefPubMed
23.
Zheng J, Bizzozero OA: Accumulation of protein carbonyls within cerebellar astrocytes in murine experimental autoimmune encephalomyelitis. J Neurosci Res. 2010, 88: 3376-3385. 10.1002/jnr.22488.CrossRefPubMedPubMedCentral
24.
Dasgupta A, Zheng J, Perrone-Bizzozero NI, Bizzozero OA: Increased carbonylation, protein aggregation and apoptosis in the spinal cord of mice with experimental autoimmune encephalomyelitis. ASN Neuro. 2013, 5: e00111-CrossRefPubMedPubMedCentral
25.
Li S, Vana AC, Ribeiro R, Zhang Y: Distinct role of nitric oxide and peroxynitrite in mediating oligodendrocyte toxicity in culture and in experimental autoimmune encephalomyelitis. Neuroscience. 2011, 184: 107-119.CrossRefPubMed
26.
Toshniwal PK, Zarling EJ: Evidence for increased lipid peroxidation in multiple sclerosis. Neurochem Res. 1992, 17: 205-207. 10.1007/BF00966801.CrossRefPubMed
27.
Calabrese V, Raffaele R, Cosentino E, Rizza V: Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int J Clin Pharmacol Res. 1994, 14: 119-123.PubMed
28.
Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F: Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010, 120: 301-304. 10.3109/00207451003695690.CrossRefPubMed
29.
Seven A, Aslan M, Incir S, Altıntaş A: Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy. Folia Neuropathol. 2013, 51: 58-64.CrossRefPubMed
30.
Greco A, Minghetti L, Puopolo M, Cannoni S, Romano S, Pozzilli C, Levi G: Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. J Neurol Sci. 2004, 224: 23-27. 10.1016/j.jns.2004.05.016.CrossRefPubMed
31.
Mattsson N, Haghighi S, Andersen O, Yao Y, Rosengren L, Blennow K, Praticò D, Zetterberg H: Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci Lett. 2007, 414: 233-236. 10.1016/j.neulet.2006.12.044.CrossRefPubMed
32.
Sbardella E, Greco A, Stromillo ML, Prosperini L, Puopolo M, Cefaro LA, Pantano P, De Stefano N, Minghetti L, Pozzilli C: Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Mult Scler. 2013, 19: 411-417. 10.1177/1352458512457721.CrossRefPubMed
33.
Pennisi G, Cornelius C, Cavallaro MM, Salinaro AT, Cambria MT, Pennisi M, Bella R, Milone P, Ventimiglia B, Migliore MR, Di Renzo L, De Lorenzo A, Calabrese V: Redox regulation of cellular stress response in multiple sclerosis. Biochem Pharmacol. 2011, 82: 1490-1499. 10.1016/j.bcp.2011.07.092.CrossRefPubMed
34.
Gonzalo H, Brieva L, Tatzber F, Jové M, Cacabelos D, Cassanyé A, Lanau-Angulo L, Boada J, Serrano JC, González C, Hernández L, Peralta S, Pamplona R, Portero-Otin M: Lipidome analysis in multiple sclerosis reveals protein lipoxidative damage as a potential pathogenic mechanism. J Neurochem. 2012, 123: 622-634. 10.1111/j.1471-4159.2012.07934.x.CrossRefPubMed
35.
Kalousová M, Havrdová E, Mrázová K, Spacek P, Braun M, Uhrová J, Germanová A, Zima T: Advanced glycoxidation end products in patients with multiple sclerosis. Prague Med Rep. 2005, 106: 167-174.PubMed
36.
Ljubisavljevic S, Stojanovic I, Vojinovic S, Stojanov D, Stojanovic S, Cvetkovic T, Savic D, Pavlovic D: The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF. Neurochem Int. 2013, 62: 988-997. 10.1016/j.neuint.2013.02.025.CrossRefPubMed
37.
Jiménez-Jiménez FJ, de Bustos F, Molina JA, de Andrés C, Gasalla T, Ortí- Pareja M, Zurdo M, Porta J, Castellano-Millán F, Arenas J, Enríquez de Salamanca R: Cerebrospinal fluid levels of alpha-tocopherol in patients with multiple sclerosis. Neurosci Lett. 1998, 249: 65-67. 10.1016/S0304-3940(98)00370-X.CrossRefPubMed
38.
de Bustos F, Navarro JA, de Andrés C, Molina JA, Jiménez-Jiménez FJ, Ortí-Pareja M, Gasalla T, Tallón-Barranco A, Martínez-Salio A, Arenas J: Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. Eur Neurol. 1999, 41: 44-47.CrossRefPubMed
39.
Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D'Urso S, Vagnozzi R, Uitdehaag B, Lazzarino G: Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem. 2009, 42: 2001-2006.CrossRef
40.
Kastenbauer S, Kieseier BC, Becker BF: No evidence of Increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis. J Neurol. 2005, 252: 611-612. 10.1007/s00415-005-0697-z.CrossRefPubMed
41.
Kuehl BL, Paterson JW, Peacock JW, Paterson C, Rauth AM: Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer. 1995, 72: 555-561. 10.1038/bjc.1995.373.CrossRefPubMedPubMedCentral
42.
Stavropoulou C, Zachaki S, Alexoudi A, Chatzi I, Georgakakos VN, Terzoudi GI, Pantelias GE, Karageorgiou CE, Sambani C: The C609T inborn polymorphism in NAD(P)H:quinone oxidoreductase 1 is associated with susceptibility to multiple sclerosis and affects the risk of development of the primary progressive form of the disease. Free Radic Biol Med. 2011, 51: 713-718. 10.1016/j.freeradbiomed.2011.04.043.CrossRefPubMed
43.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001, 50: 121-127. 10.1002/ana.1032.CrossRefPubMed
44.
Martínez C, García-Martín E, Benito-León J, Calleja P, Díaz-Sánchez M, Pisa D, Alonso-Navarro H, Ayuso-Peralta L, Torrecillas D, Agúndez JA, Jiménez-Jiménez FJ: Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis. Neuromolecular Med. 2010, 12: 217-223. 10.1007/s12017-009-8095-9.CrossRefPubMed
45.
García-Martín E, Martínez C, Benito-León J, Calleja P, Díaz-Sánchez M, Pisa D, Alonso-Navarro H, Ayuso-Peralta L, Torrecillas D, Agúndez JA, Jiménez-Jiménez FJ: Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. European Jouirnal of Neurol. 2010, 17: 335-338. 10.1111/j.1468-1331.2009.02720.x.CrossRef
46.
García-Martín E, Lorenzo-Betancor O, Martínez C, Pastor P, Benito-León J, Millán-Pascual J, Calleja P, Díaz-Sánchez M, Pisa D, Turpín-Fenoll L, Alonso-Navarro H, Ayuso-Peralta L, Torrecillas D, Lorenzo E, Plaza-Nieto JF, Agúndez JA, Jiménez-Jiménez FJ: LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis. BioMed Central Neurol. 2013, 13: 34-10.1186/1471-244X-13-34.CrossRef
47.
García-Martín E, Agúndez JA, Martínez C, Benito-León J, Millán-Pascual J, Calleja P, Díaz-Sánchez M, Pisa D, Turpín-Fenoll L, Alonso-Navarro H, Ayuso-Peralta L, Torrecillas D, Plaza-Nieto JF, Jiménez-Jiménez FJ: Vitamin D3 receptor (VDR) gene rs2228570 (Fok1) and rs731236 (Taq1) variants are not associated with the risk for multiple sclerosis: results of a new study and a meta-analysis. Public Library of Sci One. 2013, 8: e65487-
48.
Agúndez JAG, Garcia-Martin E, Martínez C, Benito-León J, Millán-Pascual J, Calleja P, Díaz-Sánchez M, Pisa D, Turpín-Fenoll L, Alonso-Navarro H, Ayuso-Peralta L, Torrecillas D, Plaza-Nieto JF, Jiménez-Jiménez FJ: MAPT gene rs1052553 polymorphism is not associated with the risk for multiple sclerosis. Hum Immunol. 2013, 74: 1705-1708. 10.1016/j.humimm.2013.07.008.CrossRefPubMed
49.
Pértegas Díaz S, Pita Fernández S: Cálculo del poder estadístico de un estudio. Cad de Atención Primaria. 2003, 10: 59-63.
Metadata
Title
NQO1gene rs1800566 variant is not associated with risk for multiple sclerosis
Authors
José A G Agúndez
Elena García-Martín
Carmen Martínez
Julián Benito-León
Jorge Millán-Pascual
Patricia Calleja
María Díaz-Sánchez
Diana Pisa
Laura Turpín-Fenoll
Hortensia Alonso-Navarro
Lucía Ayuso-Peralta
Dolores Torrecillas
José Francisco Plaza-Nieto
Félix Javier Jiménez-Jiménez
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-14-87

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue

Study protocol

Study protocol: münster tinnitus randomized controlled clinical trial-2013 based on tailor-made notched music training (TMNMT)

Research article

Association between neuromyelitis optica and tuberculosis in a Chinese population

Case report

The eleventh reported case of Mulvihill-Smith syndrome in the literature

Research article

Relevance of novel inflammatory markers in stroke-induced immunosuppression

Study protocol

The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing

Case report

Role of inflammatory markers in Takayasu arteritis disease monitoring